Search results for " pertussis"
showing 10 items of 54 documents
Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.
1996
The aim of this study was to investigate pertussis-specific cell-mediated immunity in infants vaccinated with a tricomponent acellular vaccine. Infants were investigated during a primary vaccination schedule from the third month of life to the sixth month as well as before and after a booster at 15 to 24 months. This is the first report of specific cell-mediated immune responses to pertussis-related antigens in infants below the age of 12 months. Our data show that the vaccine induces T-cell responses specific for the vaccine components, detoxified pertussis toxin, filamentous hemagglutinin, and pertactin, that increase progressively over the course of the vaccination schedule. In contrast …
Characterization of the Purified Fourth Component of Guinea Pig Complement* *Supported by Deutsche Forschungsgemeinschaft (grant Kl 124/9).
1970
Publisher Summary A strain of rabbits deficient in complement was discovered in Freiburg, Germany in 1961. A second, clearly unrelated, strain was reported in Mexico. Both these strains are deficient in C6. A further complement-deficient rabbit was found by chance in Cambridge. This paper presents some data on the colony bred from this animal. C6 was partially purified from rabbit serum by chromatography on DEAE Cellulose and hydroxyapatite. Antibody to rabbit C6 in deficient rabbits was raised by four weekly injections of alum precipitated C6 with Bordetella pertussis as adjuvant into the knee joints, followed by three intravenous injections of the alum precipitated material without B. per…
Acute Laryngitis in the Rat Induced by Moraxella catarrhalis and Bordetella pertussis: Number of Neutrophils, Dendritic Cells, and T and B Lymphocyte…
1999
Infectious laryngotracheitis results in fulminant respiratory distress. During the disease, the subglottic mucosa is selectively infected and swollen, the reason for this preference being unknown. Therefore, in the present study the immunoreaction of the laryngeal mucosa was studied in the rat after inhalation of either heat-killed Moraxella catarrhalis (PVG rats) or application of viable Bordetella pertussis (BN rats). The number of neutrophils, macrophages, dendritic cells, and T and B lymphocytes was determined in the mucosa of the supraglottic, glottic, and subglottic area of the larynx as well as in the trachea. After application of the pathogens, the mucosa of the subglottic area was …
Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines
1998
Abstract A large, randomized, placebo-controlled clinical trial in Italy on two three-component pertussis vaccines, given as DTaP in infancy, one manufactured by SmithKline and Beecham (SB) and one by Chiron Biocine (CB), found each vaccine to be 84% efficacious through the average age of 24 months. The cohort of children envolled in the trial was followed with unmodified case ascertainment procedures for nine additional calendar months, during which partial unblinding occurred, for the unvaccinated randomized group. For the DTaP groups, the specific vaccine assignment remained double-blinded throughout the entire additional observation period. Pertussis was defined as paroxysmal cough last…
Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough
2003
The study of antigen specific IgG subclass distribution during disease, or during any other natural or artificial immunisation, can provide useful information on the kind of the immune response and the expected levels of protection. This is particularly true for diseases, such as pertussis in which the mechanisms underlying specific defence are still not completely understood. An investigation was therefore performed to evaluate the IgG subclass response to pertussis toxin (PT) in sera from 89 healthy vaccinated children and 131 vaccinated or unvaccinated children convalescent after a confirmed B. pertussis symptomatic infection. Antibody titres were expressed in arbitrary ELISA units/ml, a…
Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine.
1994
The safety and immunogenicity of an acellular pertussis vaccine containing the genetically detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together with diphtheria and tetanus toxoids, were compared with those of a whole-cell pertussis component-diphtheria-tetanus vaccine. Four hundred eighty infants were enrolled into this prospective, multicenter, double-blind study. Each infant was randomly given three doses of one of the two vaccines at 2, 4, and 6 months of age. Both local and systemic adverse reactions, reported within 48 hours and 7 days of each injection, were less frequent after the acellular vaccine than after the whole-cell vaccine. The enzyme-lin…
Pertussis in adults with persistent cough: a prospective follow up study in primary care.
2009
Despite high coverage of pertussis vaccine, B. pertussis has remained endemic and adults are recognized as reservoir for infection among incompletely immunized infants. Between November 15th 2004 and November 14th 2006, 37 general practitioners, attending 56,658 adults, recruited all patients with persistent cough. A diagnosis of pertussis was considered in those with an unexplained cough, lasting 14 or more days and a positive polymerase chain reaction (PCR) or enzyme-linked immunosorbent assay (ELISA) IgG anti-Pertussis Toxin (PT). During the period of the study 86 patients presented with persistent cough (106 cases per 100,000 person-years). According to laboratory criteria, 35% were cla…
Efficacy of Acellular Pertussis Vaccine in Early Childhood After Household Exposure
1996
Objective. —To evaluate the efficacy of a three-dose primary vaccination with a diphtheria-tetanus tricomponent acellular pertussis vaccine against "typical" pertussis, defined as a spasmodic cough of 21 days or longer with confirmation of Bordetella pertussis infection by culture or serology. Design. —Passive monitoring for suspected first household (index) cases of typical pertussis in six areas in Germany comprising 22 505 children vaccinated with study vaccine at 3, 4, and 5 months of age. Blinded, prospective follow-up of household contacts of index cases for incidence and progression of pertussis. Setting. —Six areas in Germany with a high incidence of pertussis. Subjects. —Four hundr…
European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations.
2008
A standardisation process, already developed during the earlier European Sero-Epidemiology Network (ESEN) project, was employed with a more robust algorithm to harmonise results of pertussis serological assays performed in 12 European and non-European countries. Initially, results from each country's own assay were compared with those obtained at the reference laboratory by means of an in-house pertussis toxin (PT)-based ELISA: seven countries used in-house or commercial PT-ELISAs; the other countries used assays based on Bordetella pertussis whole cell extracts (WCE) (three countries) or on combined PT-FHA (filamentous haemagglutinin) antigenic preparations (two countries). The WCE assays,…
Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine).
2009
Combination vaccines that include multiple antigens within one formulation are now widely accepted as an effective means of eliciting protection against several diseases at the same time. Owing to improvements in quality and convenient modes of administration, they have become part of routine pediatric practice. Hexavalent vaccines, including diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b antigens represent the latest advance in the development of combination vaccines. Over 8 years since its first licensure, this review looks at the immunogenicity, efficacy and safety profile of the only hexavalent pediatric vaccine currently in use--Infanrix hexa (diph…